ALEC — Alector, Inc.

Is ALEC overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of October 3, 2026

Alector, Inc. (ALEC) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Biotechnology) last closed at $1.81. The rating moved from Neutral to Oversold on September 26, 2026.

See all oversold Healthcare stocks →

AI analysis

Alector, Inc. (ALEC) is a small-cap biopharmaceutical company whose market value is heavily dependent on clinical progress and capital markets access. Near-term performance is likely to track headline-driven sentiment and financing news; investors should monitor cash runway, upcoming milestones, any partnership announcements, and macro policy developments affecting drug pricing.

Key factors

  • Pipeline-dependent valuation: equity value is driven primarily by clinical milestones and trial readouts rather than stable commercial revenue.
  • Cash runway and financing sensitivity: low share price implies likely limited liquidity and an elevated probability of future equity raises or partnering needs to fund operations.
  • Sector tailwinds for successful late-stage biologics: recent positive late-stage outcomes in specialty/rare disease space support upside for companies that can deliver confirmatory data.
  • Policy and payer pressure: ongoing U.S. Medicare negotiation and drug-pricing scrutiny could compress realized pricing and access for high-cost therapies.
  • Risk-off market tone and low volume: recent market caution reduces the chance of strong share-price rallies absent definitive catalysts.
  • Partnership and licensing optionality: business development or collaboration could materially de-risk cash needs and validate assets if executed.

Risks

  • Clinical trial failure or negative readouts that would significantly reduce future commercial potential.
  • Dilution risk from near-term financings if cash runway is insufficient, eroding existing shareholder value.
  • Adverse regulatory decisions or delays increasing time-to-market and development costs.
  • Pricing pressure from Medicare negotiation and payer cost-containment actions limiting revenue potential for high-priced therapies.
  • Competitive threats from larger biotech/pharma entrants or adjacent modality innovators that capture market share.
  • Low trading liquidity leading to heightened volatility and difficulty executing large trades without market impact.
  • Operational execution risks, including enrollment delays, manufacturing bottlenecks, or unexpected safety signals.

See today's live rating, score and targets

Members see the live hourly rating for ALEC — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.